近距离放疗推量较单纯外照射放疗改善中高危前列腺癌患者生存并降低远处转移风险
该多机构真实世界数据研究纳入2003年1月至2014年12月两家三级机构收治的1641例中高危前列腺癌患者,比较外照射放疗(EBRT,n=1148)与高剂量率近距离放疗推量(BTB,n=493)的疗效。BTB是总生存(HR 0.75;95%CI 0.63-0.88;p<0.001)、无远处转移生存(HR 0.54;95%CI 0.4-0.73;p<0.001)和无转移生存(HR 0.72;95%CI 0.61-0.85;p<0.001)的独立预后因素。倾向评分匹配后986例患者中,BTB组总生存(p<0.001)、无远处转移生存(p=0.001)和无转移生存(p<0.001)均显著更高。
要点
- BTB是总生存的独立预后因素(HR 0.75;95%CI 0.63-0.88;p<0.001)。
- BTB是无远处转移生存的独立预后因素(HR 0.54;95%CI 0.4-0.73;p<0.001)。
- 倾向评分匹配后BTB组总生存、无远处转移生存和无转移生存均显著更高。
核心结论
- 在中高危前列腺癌接受根治性放疗的患者中,近距离放疗推量与总生存、无远处转移生存和无转移生存呈强正相关。
研究设计与样本
- 多机构真实世界数据库研究,收集2003年1月至2014年12月两家三级机构收治的中危或高危前列腺癌患者数据。
- 患者接受根治性外照射放疗或近距离放疗推量,可联合或不联合雄激素剥夺治疗。
- 采用Cox回归模型和倾向评分一对一匹配后的log-rank检验评估治疗方式的影响。
主要发现
- 共分析1641例患者,其中外照射放疗组1148例,高剂量率近距离放疗推量组493例。
- 中位生存随访117.8个月(IQR 78-143.3),中位临床随访60.7个月。
- 近距离放疗推量是总生存的独立预后因素(HR 0.75;95%CI 0.63-0.88;p<0.001)。
- 近距离放疗推量是无远处转移生存的独立预后因素(HR 0.54;95%CI 0.4-0.73;p<0.001)。
- 近距离放疗推量是无转移生存的独立预后因素(HR 0.72;95%CI 0.61-0.85;p<0.001)。
关键数值与推荐
- 近距离放疗推量组总生存优于外照射放疗组(HR 0.75;95%CI 0.63-0.88;p<0.001)。
- 近距离放疗推量组无远处转移生存优于外照射放疗组(HR 0.54;95%CI 0.4-0.73;p<0.001)。
- 近距离放疗推量组无转移生存优于外照射放疗组(HR 0.72;95%CI 0.61-0.85;p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Despite several prospective trials showing a clinical benefit of combining external beam radiotherapy (EBRT) with brachytherapy boost (BTB) for the treatment of intermediate- and high-risk prostate cancer (PCa) patients, none of these trials was designed to test for a survival difference. In this study, we aimed to collect a large multi-institutional database to determine whether BT boost was associated with a statistically significant improvement in survival and a reduction of distant metastases based on real-world data. MATERIAL AND METHODS: We collected the data of patients treated for intermediate- or high-risk PCa with definitive EBRT or BTB, with or without androgen deprivation therapy (ADT), between January 2003 and December 2014 at two tertiary institutions. The statistical endpoints included overall survival (OS), freedom from distant metastases (FFDM), and metastases-free survival (MFS). The impact of treatment modality was assessed using Cox regression models and log-rank testing after one-to-one propensity score matching. RESULTS: A total of 1641 patients treated with EBRT (n = 1148) or high-dose-rate BTB (n = 493) were analyzed. The median survival and clinical follow-up were 117.8 (IQR 78-143.3) and 60.7 months, respectively. The radiotherapy modality (BTB) remained an independent prognostic factor for OS (HR 0.75; 95% CI 0.63-0.88; p < 0.001), FFDM (HR 0.54; 95% CI 0.4-0.73; p < 0.001), and MFS (HR 0.72; 95% CI 0.61-0.85; p < 0.001). After propensity score matching, the remaining 986 patients were well-balanced in terms of age, maximum PSA, ISUP grade group, and TNM T stage. OS (p < 0.001), FFDM (p = 0.001) and MFS (p < 0.001) were significantly higher in the BTB group. CONCLUSIONS: There is a strong positive association between BTB and OS, FFDM, and MFS in PCa patients treated with definitive RT for intermediate- or high-risk PCa.
引用
- Miszczyk M, Magrowski Ł, Krzysztofiak T, et al. Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients. Radiother Oncol. 2023. PMID: 36963442. doi:10.1016/j.radonc.2023.109632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。